HPV Vaccination Best Practices Learning Collaborative
AMGA and the National HPV Vaccination Roundtable launched an 18-month learning collaborative to improve HPV vaccination rates among adolescents served by medical groups and integrated health systems. This Collaborative is based off the successful work undertaken in AMGA’s Adult Immunization Best Practices Learning Collaborative which resulted in 5.5 million vaccinations administered or documented over a three year period. Funding was made possible by the Centers for Disease Control and Prevention under CFDA # 93.421 - Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health, Cooperative Agreement grant number 6 NU38OT000283-02-01.
Eight healthcare organizations were recruited to participate in the collaborative and to implement best practice interventions and strategies.
What We Already Know
Fourteen million Americans acquire HPV infections each year. We do not know what infections will clear and which infections will not. We do know that the HPV vaccine includes strains that cause over 90% of HPV cancers, mitigating patient risk. Approximately 92 people each day are diagnosed with an HPV-attributable cancer. These patients and their families face the emotional impact of a cancer diagnosis, the challenges of cancer treatment and the possibility of death. Health systems with missions to improve health, provide high-quality care, and serve their communities have been caring for these patients as well as managing the high financial costs that accompany cancer care. Health systems are well positioned to expedite HPV vaccine uptake and help eliminate HPV cancers.
To help participants succeed, AMGA’s collaborative offers a wealth of resources and support, such as:
- Two in-person meetings: February 2020 (kick-off) January 2021 (wrap-up)
- Every other month webinars
- Online resources - a dedicated website for Collaborative participant material-sharing and a listserv for idea-sharing and collaboration
- Consultation in the field from AMGA, National HPV Vaccination Roundtable, and external experts
- Quality Improvement tools, resources, and outreach
We have convened an advisory committee of industry and clinical experts that will provide guidance to the Collaborative on the development of objectives and educational content. The Committee includes:
- Kara Elam, Ph.D., M.P.H., M.S.
ORISE Fellow in Vaccine Policy,
Office of Infectious Disease & HIV/AIDS Policy (OIDP),
U.S. Department of Health & Human Services
- Melissa Gilkey, Ph.D.
Assistant Professor, Department of Health Behavior
University of North Carolina’s Gillings School of Global Health
- Sarah Kobrin, Ph.D., M.P.H.
Chief of Health Systems & Research Branch
National Cancer Institute
- Jason Maxwell, M.D.
Department Chair of Pediatrics and Practices
HealthPartners Como Clinic
- Kristin Oliver, M.D., M.H.S.
Icahn School of Medicine at Mount Sinai, Department of Environmental Medicine and Public Health, Department of Pediatrics
- Andrea Polkinghorn, B.S.N., R.N.-BC
Immunization Strategy Leader
- Melinda Wharton, M.D.
Director, Immunization Services Division, NCIRD
Centers for Disease Control and Prevention
If you have questions or need further information, contact Erin Leaver-Schmidt at email@example.com or by phone at 703.838.0033 ext. 390.